Introduction
============

Sequential accumulation of somatic mutations in certain tumor suppressor genes and oncogenes during cancer development was described by Vogelstein and Fearon [@B1], [@B2]. This model has been confirmed by later studies [@B3], [@B4], and is considered fundamental to modern cancer genomics. With the development of high throughput and economical next generation sequencing (NGS) methods, innumerable different somatic mutations have been discovered for hundreds of genes in several kind of tumors, so the genetic model of cancer have been refined [@B5], [@B6]. In colon cancer, a limited number of oncogene and tumor suppressor gene mutations are reported to be crucial in the development of the disease [@B7]. Moreover, analysis a number of these mutations has become essential in directing targeted cancer therapy. To support further clinical implementation for targeted therapy, development of low cost targeted NGS library preparation techniques is needed focusing on limited number, disease-specific genes [@B8].

Three of the most popular small-scale NGS instruments suitable for targeted sequencing are the MiSeq Desktop Sequencer (Illumina, San Diego, CA, USA), the Ion PGM™ System (Thermo Fisher Scientific, Waltham, MA, USA) and the GS Junior Instrument (Roche Applied Science, Penzberg, Germany). For each system, several targeted library preparation methods exist, and some predesigned panels are commercially available as well, but many of them are not applicable for the GS Junior since its capacity is the lowest. In addition, in case of GS Junior and Ion PGM, false positive insertion or deletion mutations can also be detected - especially for longer homopolymers - since the number of identical nucleotides following each other is calculated from the signal intensity detected after dispensing each nucleotide [@B9], [@B10].

Recently, a multiplex PCR-based library preparation panel, the Ion AmpliSeq Cancer Panel has become available for the Ion Torrent platform [@B11]. Another predesigned library preparation panel is the Human Colorectal Cancer Panel (Qiagen, Hilden, Germany). However, the lower capacity of the GS Junior instrument renders these panels less effective on this platform. While a sequence capture panel is available for screening cancer-related somatic mutations for the GS Junior [@B12], multiplex PCR-based panels are only available for germline mutations, such as *APC* or *BRCA1* and *BRCA2* [@B13].

In this study, we aimed to design and test a multiplex PCR-based library preparation panel for the GS Junior NGS instrument in order to enable rapid, simultaneous and economic sequencing of colon cancer mutation hot spots.

Materials and Methods
=====================

Selection of panel genes and mutation hot spot regions
------------------------------------------------------

The selection of target genes was based on mutation data in the Catalogue of Somatic Mutations in Cancer (COSMIC) database [@B14]. Genes were selected based on their mutation frequencies in colorectal cancer (CRC) or if they were routinely investigated in targeted oncotherapy. Since the capacity of the GS Junior instrument is limited, our objective was to reduce the length of target regions and maximize the effectiveness of the panel by focusing primarily on the mutation hot spots of these genes (Table [1](#T1){ref-type="table"}).

Design and preparation of the multiplex mutation hot spot PCR panel primers
---------------------------------------------------------------------------

Ion Ampliseq Designer (Thermo Fisher Scientific) was used to generate multiplex PCR primer sequences to amplify selected gene regions (Table [2](#T2){ref-type="table"}). Ampliseq primers comprising the panel were obtained from Thermo Fisher Scientific.

Tissue sample collection
------------------------

Biopsy samples were taken in the course of routine colonoscopy examinations. Histological diagnoses were established by experienced pathologists. Microsatellite status analysis of adenoma and CRC samples was performed by immunohistochemistry as described previously [@B15]. A sample was scored microsatellite stable (MSS) if all four main mismatch repair genes (*MLH1, MSH2, MSH6*and *PMS2*) proved to be positive at protein level. All of our samples selected for this study were MSS. Colon tumor samples (left-sided, moderately differentiated, Dukes A-C stages, n=17), adenoma samples (n=33) and histologically normal adjacent tissue (NAT, n=8) originated from the area at least 10 cm far away from the tumor were analyzed. Adenoma samples were histologically classified as tubular adenomas with low-grade (AD-LGD, n=16) or high-grade (AD-HGD, n=6) dysplasia and serrated adenomas (AD-serr, n=11). Biopsy samples were stored in RNAlater Reagent (Qiagen) at -80°C until utilization. In addition, two cell lines, HT-29 (ATCC® HTB-38™) and Caco-2 (ATCC® HTB-37™) were also investigated as control samples, with known mutation profiles. The study was approved by the Semmelweis University Regional and Institutional Committee of Science and Research Ethics (ETT TUKEB 23970/2011). Written informed consent was provided by all patients.

Genomic DNA isolation
---------------------

For genomic DNA isolation, the High Pure PCR Template Preparation Kit (Roche) was used according to the manufacturer\'s instructions. Concentrations of isolated DNA were measured using a Qubit fluorometer (Thermo Fisher Scientific) with Qubit dsDNA HS Assay.

Multiplex PCR
-------------

Multiplex PCR reactions were performed in two tubes for each sample by using 12.5 μl of GeneRead Gene Panel Mastermix (Qiagen), 2.5 μl of pre-made primer pool1 or primer pool2 (Table [2](#T2){ref-type="table"}), 7 μl of water and 3 μl of DNA samples (containing 10-20 ng of isolated DNA). The final volume was 25µl. Multiplex PCR amplification was carried out with the following thermocycling conditions in an Eppendorf Mastercycler ep gradient S instrument (Eppendorf, Hamburg, Germany): 95°C for 10 minutes, followed by the amplification 95°C for 15 sec and 60°C for 2 minutes in 30 cycles, then 72°C for 10 minutes and 4°C forever store.

GS Junior library preparation and sequencing
--------------------------------------------

The concentration of multiplex PCR products was measured on a Qubit fluorometer using High Sensitivity dsDNA reagent and molarity was calculated. The amplicons for a given sample produced in each of the two multiplex reactions were pooled at an equimolar ratio. Before adaptor ligation, 30-50 μl of pooled PCR products were purified with AMPure beads (Agencourt, Beckman Coulter Genomics, Pasadena, CA, USA) according to the manufacturer\'s standard protocol and NEBNext® dA-Tailing Module was used to add 3\' adenine overhang (New England Biolabs (NEB), Ipswich, MA, USA). After dA-Tailing, PCR products were purified by AMPure beads, then 5\' phosphorylated with T4 Polynucleotide Kinase (NEB) in T4 DNA Ligase Reaction buffer (NEB B0202) at 37°C for 30 minutes. After this incubation, 1 μl of Rapid Library Molecular Identifier (RL_MID) adaptor and 0.5 μl of high concentration T4 DNA Ligase (NEB) were added to the mixture, suspended and incubated overnight at 17°C. After ligation, PCR libraries were purified twice with AMPure beads and analyzed using the High Sensitivity DNA Chip on the Agilent Bioanalyzer (Agilent, Santa Clara, CA, USA) to assess sample library quality.

Library quantification was determined by fluorometric measurements using Qubit dsDNA HS reagent and libraries were mixed at equimolar ratios. Identification of each library was based on library specific MID adaptors. Amplicon library pools were then prepared at a 2 DNA molecule per bead ratio using the Lib-L emPCR Kit (Roche), following the manufacturer\'s instructions, though modified to use a lower concentration of Amplification primer (40 μl primer instead of 80 μl stated in the standard protocol). This modification was necessary because of the usage of short amplicons to prevent excess template amplification during emPCR. Bead enrichment and sequencing were performed using GS Junior Titanium Sequencing Kit (Roche) and the method described in the Sequencing Method Manual, GS FLX Titanium Series. Eight samples were sequenced in parallel in one GS Junior run.

Evaluation of GS Junior sequencing results
------------------------------------------

The Amplicon Variant Analyzer software (AVA, Roche) was used to identify variants with the following parameters: minimum variant read counts: 5; minimum variants: 5%, forward and reverse.

Verification of variants identified by the NGS panel
----------------------------------------------------

To validate the results of our NGS panel with an alternative method, unknown, presumably novel variants, as well as *APC, KRAS, NRAS* and*BRAF* variants of CRC samples were re-sequenced with conventional sequencing instruments. In order to avoid technical artefacts, independent primer sets were used for this validation different from those used for the multiplex panel (Table [4](#T4){ref-type="table"}).

*APC* variants were re-sequenced using M13 tagged PCR primers (Table [4](#T4){ref-type="table"}) followed by a standard Sanger sequencing protocol. For re-sequencing *KRAS*codon 12, codon 13 and *BRAF*mutations, we used PCR and sequencing primer sets published by Susan D. Richman and colleagues followed by pyrosequencing [@B16]. In case of *NRAS* mutations a previously published primer set and pyrosequencing was used as well [@B17]. Before both Sanger and pyrosequencing reactions, PCR amplification was executed using 20-50 ng sample DNA per reaction, AmpliTaq Gold® 360 Master Mix (Thermo Fisher Scientific) and the appropriate PCR primers in 0.2 μM final concentrations. Thermal cycling conditions for all amplicons were as follows: 95°C for 12 minutes followed by 40 cycles of 95°C for 10 seconds, 58°C for 20 seconds, and 72°C for 20 seconds. The quantity and quality of PCR products were verified on a 2% agarose gel. Sanger sequencing was performed with BigDye® Terminator v3.1 Cycle Sequencing Kit (Thermo Fisher Scientific). Sequencing was carried out on an Applied Biosystems® 3500 Genetic Analyzer (Thermo Fisher Scientific). Sanger sequencing results were analyzed using the BioEdit sequence alignment software (Ibis Biosciences, Carlsbad, CA, USA). For pyrosequencing, a standard protocol was applied [@B18], and the PyroMark Q24 Software (Qiagen) was used to evaluate pyrosequencing results.

Results
=======

Technical performance of the PCR panel
--------------------------------------

The total length of target regions of the constructed panel was 3,004 bp, where the mutation hot-spots of the 12 selected genes were amplified by 39 PCR primer pairs distributed into 2 multiplex PCR reactions. The number of reads for a sequencing run passing the quality filters was typically around 80,000. In each sequencing run, amplicons from 8 samples were sequenced in parallel. Samples had 9,768 AQ20 reads on average, and total read number was above 4,000 in 83% of samples, except for normal samples that were sequenced in lower depth (Figure [1](#F1){ref-type="fig"}A). Genome regions recognized by the amplicons were covered by an average of 224 reads, with a relatively high standard deviation of 209. Five amplicons failed consistently to be sequenced with a minimum coverage of 40 in 25% of the samples (APC_3; TP53_1\_1; MSH6_1; SMAD2 and TP53_3\_2) (Figure [1](#F1){ref-type="fig"}B). Redesigning these primer pairs would be reasonable in the future in order to achieve better sequencing depths of these gene regions.

Homopolymer errors
------------------

In order to calculate and quantify the inaccuracy of GS Junior sequencing at homopolymer regions, the frequency of false positive insertion or deletion calls was counted at these regions in mutation free normal samples. The frequency of these miscalls in the target area were estimated. The most miscalls, 1.4 / 3,004 bp were observed for 4-mer homopolymers (Figure [2](#F2){ref-type="fig"}A), which is due to the relative high frequency (35 / 3,004bp) of four base-long homopolymers and the high inaccuracy of 454 sequencing at this length of homopolymers. The probability of miscalling or inaccuracy was calculated for homopolymers of each lengths separately (2-mer, 3-mer, 4-mer, etc.) by dividing the frequency of false positive calls with the frequency of the given homopolymer. In case of 4-mers the inaccuracy was found to be 3.9 % by AVA default settings. It means that around 4% of 4-mer homopolymer repeats are miscalled (Figure [2](#F2){ref-type="fig"}B).

Control cell lines
------------------

Two cell lines, HT-29 and Caco-2 were tested using our panel. According to the COSMIC database, there are three mutations at the target region, *APC*p.T1556fs\*3, *BRAF* V600E and *TP53* R273H in the HT-29 cell line, while the Caco-2 cell line has only one mutation in *SMAD4* (D351H). These mutations were corroborated by our results, except for the *APC* insertion, which was fallen into a 6-mer adenine homopolymer repeat. The coverage at this variant was 857, and the good quality of reads in case of HT-29 sample indicates the correct technical result (data not presented).

Variants detected by the GS Junior panel
----------------------------------------

In total, 34 distinct variants were detected by our panel by sequencing the 58 colonic samples (Table [3](#T3){ref-type="table"}). One proved to be a single nucleotide polymorphism (SNP) (*APC* c.4479:G\>A, SNP reference number: rs41115). Three of all mutations were not registered either in COSMIC, the Human Gene Mutation Database (HGMD), or in the SNP database, so are presumably novel mutations detected for the first time (*CTNNB1* c.47C\>T; *FBXW7* c.1740:C\>G and*SMAD4*c.413C\>G). As detailed later in this article, two of these unknown variants were confirmed by Sanger sequencing (Figure [5](#F5){ref-type="fig"}), but not the *CTNNB1* c.47C\>T variant that was found to be wild type (Figure [7](#F7){ref-type="fig"}E). Another *APC* variant (c.3871C\>T nonsense mutation) was a potential germline mutation found in a normal colonic sample with 58% allele frequency.

Number of mutations per sample in different stages
--------------------------------------------------

Our results demonstrate that the average number of mutations found by the panel is higher in CRC samples, than in adenomas or normal samples (Figure [3](#F3){ref-type="fig"}A). Accordingly, the proportion of samples bearing 3 mutations was higher in the CRC group, than in adenomas (Figure [3](#F3){ref-type="fig"}B). Only 1 of 8 normal samples had a mutation in *APC* with 58% allele frequency (c.3871C\>T causing Q1291stop), which can be a germline mutation. In case of adenomas, the greatest number of mutations per sample and the highest proportion of samples having three mutations were observed in the serrated group (Figure [3](#F3){ref-type="fig"}C, 3D).

Frequency of mutations in different pathology groups
----------------------------------------------------

The portion of mutated samples in the CRC group was as follows: *APC*: 29.4%; *TP53*: 52.9%; *KRAS*: 29.4%; *SMAD4*: 17.6%; *BRAF*: 5.9%. In adenomas, these data were slightly different: *APC*: 30.3%; *TP53*: 15.2%; *KRAS*: 21.2%; *SMAD4*: 6.1%; *BRAF*: 9.1% (Figure [4](#F4){ref-type="fig"}A). *APC* was found to be the most frequently mutated gene. Its mutations affected both adenoma and CRC samples equally (30.3% and 29.4%, respectively), moreover, one of the normal samples as well. Within the adenoma group, the frequency of *APC* mutations was highest in AD-LG and AD-HGD samples (30% and 50%, respectively), while slightly lower in serrated adenomas (18%) (Figure [4](#F4){ref-type="fig"}B). The frequency of *TP53* mutations showed the highest difference between adenoma and CRC samples (15.2% and 52.9% respectively). The highest frequency of *BRAF* mutations was found in serrated adenomas and AD-HGD samples (18% and 17%, respectively), while in CRC it was found to be not more than 6% (Figure [4](#F4){ref-type="fig"}A and 4B).

In addition, a notable difference was found between the mutation pattern of serrated and non-serrated adenomas. While *TP53* and *FBXW7* were mutated characteristically in serrated adenomas, *KRAS* and *SMAD4* mutations occurred exclusively in non-serrated adenomas (AD-HGD and AD-LGD-s). However, each of the four genes was often mutated in CRC samples.

Re-sequencing of variants
-------------------------

To validate our results *APC, KRAS, NRAS*and *BRAF* mutations of CRC samples as well as the unknown *CTNNB1, FBXW7* and *SMAD4* mutations were re-sequenced by Sanger or PyroMarkQ24 sequencing instruments with primer sets different from the ones used for the panel (Table [4](#T4){ref-type="table"}).

In case of *APC,* all mutations and SNP-s detected in CRC samples with our NGS panel were Sanger sequenced providing similar results (Figure [S1](#SM1){ref-type="supplementary-material"}). Moreover, no other *APC* variants were detected by Sanger re-sequencing than those by the NGS panel. Two of the three unknown, supposedly novel mutations (*FBXW7* c.1740:C\>G and*SMAD4*c.413C\>G) were confirmed by Sanger unambiguously too (Figure [5](#F5){ref-type="fig"}).

Five *KRAS* mutations (Figure [6](#F6){ref-type="fig"}A) together with the only *BRAF* and *NRAS* mutations (Figure [6](#F6){ref-type="fig"}B and C) among CRC group were also successfully verified by pyrosequencing. One *KRAS* mutation (c.35G\>A) and the *CTNNB1* variants proved to be false positive mutation calls, since wild type sequences were detected by PyroMark and Sanger re-sequencing (Figure [7](#F7){ref-type="fig"}).

On the whole, 22 variants were confirmed and two (*KRAS* 35G\>A and *CTNNB1* 47C\>T) proved to be false positive mutation calls in the course of re-sequencing (Table [3](#T3){ref-type="table"}). It means that the specificity of our panel is around 92%, and the sensitivity can be 100%, since no other variants were detected with alternative sequencing methods. Data of the two false positive mutations is expanded in more details in Figure [7](#F7){ref-type="fig"}. In the CRC_55 sample two *KRAS* mutations (35G\>A and 38G\>A) were visible on the 454 sequencing alignment with 13% and 6% allele frequencies, respectively (Figure [7](#F7){ref-type="fig"}A). However, only the mutant allele at position 38 but not at 35 was verified by Sanger sequencing (Figure [7](#F7){ref-type="fig"}C) and pyrosequencing (Figure [7](#F7){ref-type="fig"}D). In AD-serr_39 sample, the 47C\>T variant passed the AVA criteria and was annotated as a mutation by the GS Junior (Figure [7](#F7){ref-type="fig"}B), but not by Sanger sequencing (E). In case of this latter mutation, 6 other variants were also apparent on the AVA global alignment, which suggests poor sequencing quality. These other variants were then filtered out, since these were detected only unidirectionally.

Discussion
==========

The number of disease-specific NGS applications is rising. In contrast with affinity enrichment techniques, multiplex PCR-based library preparation for targeted sequencing enables detection of sequence variants from as low as 10 ng input DNA [@B19]. In the present study, we constructed a mutation hot spot sequencing panel and tested it using 60 normal, adenoma- or adenocarcinoma colonic tissue samples and the GS Junior NGS platform. The panel comprised frequently mutated regions of 12 selected genes by sequencing samples with 39 amplicons.

To achieve a medium sequencing depth with an average of 250 times coverage, eight samples were sequenced in parallel.

In the course of testing, one of the main issues was the unexpectedly high deviation in the read number of different amplicons. As a consequence, analysis of 5 / 39 amplicons failed consistently due to their low coverage. This ratio of failed amplicons can be reduced either by the reduction of amplicons or samples sequenced at once, or by further optimizing the library construction method. Reducing the number of samples sequenced in parallel from 8 to 4 could raise the average sequencing depth up to a 500 times coverage. Another way to reduce the fluctuation in sequencing depth of different amplicons is to change the library preparation method from adaptor ligation to a two-step, PCR-based method using universal tailed amplicons [@B20].

It is well known that 454 and Ion sequencing methods are challenged in homopolymer regions [@B21]-[@B23] and therefore, detection of insertions or deletions affecting these regions is difficult, especially in case of longer homopolymers. Accordingly, in the course of cell line sequencing, the only mutation that our colon panel was not able to detect was an insertion affecting a 6-mer adenine homopolymer. In order to estimate the limit of homopolymer sequencing, we calculated the possibility of homopolymer miscalling as a function of their real length. We estimated a noticeable increase in the uncertainty of GS Junior sequencing from 4 base long homopolymers by counting the false positive insertion / deletion calls in normal colonic samples. Thus, we concluded that our panel is not able to detect insertions or deletions affecting 4 bases or longer homopolymers. Similar results were found about homopolymer errors by re-sequencing of an *E. coli* strain [@B10]. Higher coverage of homopolymer regions did not influence the accuracy of their sequencing appreciably.

Despite the variance in read numbers and the homopolymer issue, novel mutations were determined by the panel. The *FBXW7* c.1740:C\>G causes a H580Q substitution in the gene product. The *SMAD4*c.413C\>G substitution is a nonsense mutation, and forms a stop codon (TCA\>TGA) producing a truncated protein with 137 amino acids in length.

In addition to the discovery of new mutations, the frequency of gene mutations estimated by our panel in CRC samples corroborated with literature data. According to a study based on The Cancer Genome Atlas (TCGA) data, the mutation frequency in MSS CRC is in a similar range to those estimated by our panel: 60% (TCGA) vs. 53% (our data) in case of *TP53*; 43% vs. 29% (for *KRAS*); 11% vs. 24% (*FBXW7*); 10% vs. 18% (*SMAD4*); 3% vs. 5% (*BRAF*); 4% vs. 0% (*CTNNB1*) and 3% vs 4% (*NRAS*) [@B24]. A remarkable difference between our and TCGA data was only found in case of *APC* (81% vs. 29%). The lower frequency detected by us could arise from the small target area investigated by the GS Junior panel. TCGA data are from transcriptome sequencing and based on those results, only 44% of the mutations falls into our target area (Figure [S2](#SM1){ref-type="supplementary-material"}). Additional facts explaining this difference are the relative high frequency of insertions and deletions in *APC* homopolymer regions undetectable by our panel and the significantly lower number of CRC samples investigated in our study. Moreover, the frequency of *APC* mutations in sporadic CRC can be different in the Hungarian patient population investigated in our study. Another reason to the difference in *APC* mutation frequency could be the fact that left-sided CRC samples were analyzed in our study, while in the TCGA study tumor samples derived from all anatomical regions of the colon and rectum were included.

The highest difference in mutation frequencies was found in case of *TP53* between adenoma and CRC samples (15.2% vs. 52.9%). This finding is in harmony with literature data [@B25].

There were two genes mutated exclusively in serrated adenomas, while mutations in other genes were specific for non-serrated ones. This difference in the mutation pattern found by our panel may reflect the altered origin, and different way of development of these adenoma types, although it can also be an artificial observation considering the low number of CRC samples investigated. Nevertheless, all four genes were equally mutated in CRC samples, which suggest that both serrated and non-serrated adenomas can form malignant tumors [@B26], [@B27].

In the set of 60 colonic tissue samples, adenomas and adenocarcinomas were included, that allowed us to observe the accumulation of different mutations during the development of disease along the adenoma-carcinoma sequence, as described by the Vogelstein model [@B2]. Focusing on the total number of mutations per sample detected by our panel, such accumulation can be established, clearly seen in the transition from low- to high-grade adenomas.

In the course of re-sequencing *APC, KRAS, NRAS*and *BRAF*variants of CRC samples as well as the unknown variants, presumably new mutations were validated by alternative sequencing methods. According to these results, no other variants were detected so the sensitivity of our panel was 100%. The specificity was found to be 92%, since 22 of the 24 variants were confirmed and two of them proved to be false positive mutation calls. The read number in case of the false *KRAS*and *CTNNB1* mutation calls was 238 and 209, respectively, and variants were detected both in the forward and reverse reads with 13% and 21% frequencies. After a careful investigation of AVA data we concluded that the false *CTNNB1*mutation could be filtered out by more strict AVA variant criteria, but in that case some of the verified variants with allele frequencies below 5% would also be filtered out, decreasing the sensitivity of the panel.

In conclusion, this study summarizes the design and testing of a disease-specific, multiplex PCR based library preparation panel for NGS sequencing. This mutation panel is suitable for sequencing mutation hot spots of 12 top genes affected in CRC using the GS Junior instrument. The design and the protocol could further be developed in the future, since deviations in the sequencing depth of different regions were experienced too high. However, high sensitivity and specificity were confirmed by re-sequencing experiments and mutation frequencies were in harmony with literature data. In addition, two novel mutations were detected by this panel as well.

This work is the first multiplex PCR-based library preparation panel to screen colon cancer somatic mutations in CRC with the GS Junior instrument and can be helpful in developing NGS mutation panels for diagnostic purposes in the future.

Supplementary Material {#SM0}
======================

###### 

Supplementary figures.

###### 

Click here for additional data file.

This study was supported by the National Office for Research and Technology, Hungary (TECH_08-A1/2-2008-0114 and KMR-12-1-2012-0216 grants).

Ethics approval
===============

The study was approved by the Semmelweis University Regional and Institutional Committee of Science and Research Ethics (ETT TUKEB 23970/2011). Written informed consent was provided by all patients.

Authors\' contributions
=======================

ÁVP and AK collected colonic samples. ÁVP, TM and IK performed histological analysis of samples. BP designed the colon panel. BP and AK performed the experiments. BP, PH, AB, IC and BW analyzed data. KE and PH executed re-sequencing experiments. BP and AK wrote the manuscript. ZT, IK and BM contributed to the design and project management of the study (supplied reagents/materials/analysis tools) as well as to data analysis. All authors read the manuscript carefully.

PCR

:   polymerase chain reaction

NGS

:   next-generation sequencing

*APC*

:   adenomatous polyposis coli (gene symbol)

*BRAF*

:   B-Raf proto-oncogene, serine/threonine kinase (gene symbol)

*CTNNB1*

:   catenin (cadherin-associated protein), beta 1 (gene symbol)

*EGFR*

:   epidermal growth factor receptor (gene symbol)

*FBXW7*

:   F-box and WD repeat domain containing 7, E3 ubiquitin protein ligase (gene symbol)

*KRAS*

:   Kirsten rat sarcoma viral oncogene homolog (gene symbol)

*MSH6*

:   mutS homolog 6 (gene symbol)

*NRAS*

:   neuroblastoma RAS viral (v-ras) oncogene homolog (gene symbol)

*PIK3CA*

:   phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit alpha (gene symbol)

*SMAD2*

:   SMAD family member 2 (gene symbol)

*SMAD4*

:   SMAD family member 4 (gene symbol)

*TP53*

:   tumor protein p53 (gene symbol)

NAT

:   normal adjacent tissue

DNA

:   deoxyribonucleic acid

CRC

:   colorectal cancer

*BRCA1*

:   breast cancer 1, early onset (gene symbol)

COSMIC

:   catalogue of somatic mutations in cancer

HGMD

:   Human Gene Mutation Database

N

:   normal

AD

:   adenoma

AD-LGD

:   low-grade adenoma

AD-HGD

:   high-grade adenoma

AD-Serr

:   serrated adenoma

dsDNA

:   double-stranded DNA

emPCR

:   emulsion PCR

AQ20

:   Quality Following Alignment

AVA

:   amplicon variant analysis software

TSA

:   traditional serrated adenoma

cDNA

:   complementary DNA.

![**Sequencing depth.**Average number of reads grouped by the samples (A) and amplicons (B), respectively. Sample types are color-coded and the name of the amplicons are shown on the lower horizontal axis. Please note the logarithmic vertical scale.](jcav08p0162g001){#F1}

![**Frequency of homopolymer miscalls.**Frequency of false positive insertion or deletion variant calls at homopolymer regions with different lengths (A, black line). The frequency of different length homopolymers on the target region is illustrated with grey line. The probability of homopolymer miscalling was calculated by dividing the frequency of false positive calls with the frequency of homopolymers (B) Sequencing results of normal control samples that were considered to be free of these mutations.](jcav08p0162g002){#F2}

![**The number of mutations per sample in different pathological groups detected with the multiplex panel.**The number of mutations (A) and the number of samples bearing multiple mutations (B) increases along the adenoma-CRC sequence (red color: samples with 3 mutations; yellow: samples with 2 mutations; green: samples with 1 mutation). Similar tendency is visible in the number of mutations (C) and the proportion of multiple mutated samples (D) in different types of the adenomas. NAT: normal adjacent tumor samples; AD-LGD: low-grade adenoma samples; AD-HGD: high-grade adenoma samples; AD-serr: serrated adenoma samples; CRC: colorectal cancer samples.](jcav08p0162g003){#F3}

![**Mutation frequencies in colorectal cancer and different stages of adenomas.**The figure demonstrates the proportion of samples in different pathological groups bearing at least one mutation in a given gene. NAT: normal adjacent tumor samples; CRC: colorectal cancer samples; AD-LGD: low-grade adenoma samples; AD-HGD: high-grade adenoma samples; AD-serr: serrated adenoma samples.](jcav08p0162g004){#F4}

![**Novel mutations discovered by the panel.***FBXW7* c.1740:C\>G missense substitution (A), and *SMAD4* c.413C\>G nonsense mutation (B) were re-sequenced by Sanger sequencing protocol. The name of the variant, the sample and the allele frequency obtained by the GS Junior instrument is indicated above the electropherograms. Variable positions are signed with red arrows. The *FBXW7* mutation causes a His580Gln amino acid change in the protein sequence, while *SMAD4* mutation causes the formation of a stop codon, thus the product is a truncated protein. FW: forward sequencing primer; Rev: reverse sequencing primer.](jcav08p0162g005){#F5}

![**Re-sequencing of *KRAS*, *BRAF* and *NRAS* variants on the PyroMark Q24 instrument.***KRAS*(A)*, BRAF*(B) and *NRAS*(C) point mutations of CRC samples were validated by pyrosequencing. The name of the variant, sample and allele frequency detected by the GS Junior instrument together with the short sequence to analyze are indicated. The 5\'-3\' direction of sequencing primer and the position of the variable nucleotide peaks are signed with black horizontal and red vertical arrows, respectively. Black vertical arrows point at wild type peaks of the variable nucleotides, while red arrows show abnormal peaks denoting the presence of a mutation. Wt: wild type sequence.](jcav08p0162g006){#F6}

![**The two false positive mutations identified by the multiplex NGS panel.**AVA Global alignment of the false positive *KRAS*(A) and *CTNNB1* (B) mutations after GS Junior sequencing. Sequencing depth is illustrated with blue lines, while the allele frequency of variants is visualized as green columns. Consensus sequences of reads is also represented in the global alignment. AVA detected two *KRAS* mutations (35G\>A and 38G\>A) in CRC_55 sample (A, red arrows), but only the 38G\>A proved to be valid by Sanger sequencing (C) and pyrosequencing (D). Seven *CTNNB1* variants appeared on AVA global alignment of AD-serr_39 sample, but only the 47C\>T variant passed the AVA criteria and was annotated as a mutation (B, red arrow). Even this latter variant could not be confirmed by Sanger re-sequencing (E, black arrow), so *CTNNB1* 47C\>T was also considered a false mutation call. Black vertical arrows point at wild type peaks, while red arrows show the peaks or position of mutations detected by the corresponding method.](jcav08p0162g007){#F7}

###### 

Full cDNA sequences and target regions of selected genes.

  Gene Symbol   cDNA sequence     full cDNA   target region
  ------------- ----------------- ----------- ---------------
  APC           ENST00000457016   1-8532      3805-4737
  BRAF          ENST00000288602   1-2301      1766-1809
  CTNNB1        ENST00000349496   1-2346      14-155
  EGFR ex18     ENST00000275493   1-3633      2116-2174
  EGFR ex21     ENST00000275493   1-3633      2540-2620
  FBXW7         ENST00000281708   1-2124      1290-1418
  FBXW7         ENST00000281708   1-2124      1425-1561
  FBXW7         ENST00000281708   1-2124      1701-1812
  KRAS          ENST00000311936   1-567       9-111
  MSH6          ENST00000234420   1-4083      3240-3300
  MSH6          ENST00000234420   1-4083      2832-2938
  NRAS          ENST00000369535   1-570       21-73
  NRAS          ENST00000369535   1-570       140-239
  PIK3CA        NM_006218.1       1-3207      1566-1656
  PIK3CA        NM_006218.1       1-3207      3051-3164
  SMAD2         ENST00000262160   1-1404      895-965
  SMAD4         ENST00000342988   1-1659      968-1108
  SMAD4         ENST00000342988   1-1659      1471-1622
  SMAD4         ENST00000342988   1-1659      281-408
  TP53          ENST00000269305   1-1183      418-560
  TP53          ENST00000269305   1-1183      673-782
  TP53          ENST00000269305   1-1183      783-919

Gene Symbol, cDNA Ensembl ID or RefSeq ID of selected genes together with the target regions are listed.

###### 

List of primer sequences designed to amplify target regions.

  amplicon name   Forward primer sequence (5\'-3\')   Reverse primer sequence (5\'-3\')   Chromo-some number   Amplicon Start   Amplicon Stop   amplicon length   pool number   primer conc. in the pool (μM)
  --------------- ----------------------------------- ----------------------------------- -------------------- ---------------- --------------- ----------------- ------------- -------------------------------
  APC_1           TACAGACTTATTGTGTAGAAGATACTCCA                                           chr5                 112175067        112175239       172               Pool1         1
  APC_2           GCTAATACCCTGCAAATAGCAGAA            AAGAAAATTCAACAGCTTTGTGCCT           chr5                 112175186        112175357       171               Pool2         2
  APC_3           GCAGGGTTCTAGTTTATCTTCAGAATCA        GTGAACTGACAGAAGTACATCTGCTA          chr5                 112175302        112175468       166               Pool1         4
  APC_4           TCAGGAGACCCCACTCATGTT               GCATGGTTTGTCCAGGGCTATC              chr5                 112175422        112175585       163               Pool2         4
  APC_5           CATTATAAGCCCCAGTGATCTTCCA           GCATTTACTGCAGCTTGCTTAGG             chr5                 112175539        112175712       173               Pool1         1
  APC_6           ACTGCTGAAAAGAGAGAGAGTGGA            AGCACTCAGGCTGGATGAAC                chr5                 112175666        112175815       149               Pool2         2
  APC_7           CGGAAAGTACTCCAGATGGATTTTCTT         CATTTGATTCTTTAGGCTGCTCTGATTC        chr5                 112175769        112175930       161               Pool1         0,5
  APC_8           AGGAAAATGACAATGGGAATGAAACA          GACTTTGTTGGCATGGCAGAAAT             chr5                 112175877        112176051       174               Pool2         1
  BRAF            CATCCACAAAATGGATCCAGACAAC           GCTTGCTCTGATAGGAAAATGAGAT           chr7                 140453075        140453249       174               Pool1         0,5
  CTNNB1_1        ATTTCAATGGGTCATATCACAGATTCTT        GTAAGACTGTTGCTGCCAGTG               chr3                 41265928         41266093        165               Pool1         2
  CTNNB1_2        AGACAGAAAAGCGGCTGTTAGT              AGGTATCCACATCCTCTTCCTCAG            chr3                 41266051         41266181        130               Pool2         1
  EGFR_ex18       GTGACCCTTGTCTCTGTGTTCTT             CTGTGCCAGGGACCTTACC                 chr7                 55241580         55241754        174               Pool1         4
  EGFR_ex21       CTGGCAGCCAGGAACGTA                  GGAAAATGCTGGCTGACCTAAAG             chr7                 55259454         55259602        148               Pool2         3
  FBXW7_1\_1      GAGCACACTGTCACTATTTCAGTAACT         ACACCTTATATGGGCATACTTCCAC           chr4                 153249262        153249414       152               Pool2         2
  FBXW7_1\_2      CATGAAGATGCATACAACGCACA             GGTGGAGTATGGTCATCACAAATGAG          chr4                 153249367        153249514       147               Pool1         1
  FBXW7_2\_1      TGCAACGTGTGTAGACAGGTTT              GCCACTCTTAGGGTTTGGGATAT             chr4                 153247189        153247361       172               Pool2         2
  FBXW7_2\_2      CATGTAAACACTGGCCTGTCTCA             CCTTGACTAAATCTACCATGTTTTCTCA        chr4                 153247316        153247477       161               Pool1         1
  FBXW7_3         CACTGTCCTGTTTTGATATCCCAGA           GGATCTCTTGATACATCAATCCGTGTTT        chr4                 153245353        153245522       169               Pool1         1,25
  KRAS_kod12_13   AAAGAATGGTCCTGCACCAGTAA             AAGGCCTGCTGAAAATGACTGA              chr12                25398161         25398332        171               Pool1         1
  MSH6_1          GTCCTATGTGTCGCCCAGTA                CTTCCTCACAGCCTATTAGAATGTCATT        chr2                 48030601         48030744        143               Pool2         6
  MSH6_2          CTTTGACTCTGATTATGACCAAGCTCT         CAAATTGCGAGTGGTGAAATTCTCA           chr2                 48027918         48028092        174               Pool1         2
  NRAS_1          CCACTGGGCCTCACCTCTAT                CTGATTACTGGTTTCCAACAGGTTCT          chr1                 115258657        115258819       162               Pool1         0,75
  NRAS_2\_1       GGTAACCTCATTTCCCCATAAAGATTCA        AGTACAGTGCCATGAGAGACCA              chr1                 115256349        115256523       174               Pool1         4
  NRAS_2\_2       CCTTCGCCTGTCCTCATGTAT               CCCCAGGATTCTTACAGAAAACAAGT          chr1                 115256481        115256605       124               Pool2         0,5
  PIK3CA_1        CAGAGTAACAGACTAGCTAGAGACAATGA       CTCCATTTTAGCACTTACCTGTGACT          chr3                 178935995        178936140       145               Pool1         0,5
  PIK3CA_2        TGGAATGCCAGAACTACAATCTTTTGA         CTGTTTAATTGTGTGGAAGATCCAATCC        chr3                 178951969        178952137       168               Pool2         1
  SMAD2           CTATATGCCTTCTTGTCATTTCTACCGT        GGAGAAACCTTCCATGCATCACA             chr18                45374846         45374984        138               Pool1         3
  SMAD4_1\_1      GAAAAACTGTGTTGTGGAGTGCAA            CTCCTACCTGAACATCCATTTCAAAGTA        chr18                48591712         48591846        134               Pool2         2
  SMAD4_1\_2      CCTGAGTATTGGTGTTCCATTGCT            TCTCAATGGCTTCTGTCCTGTG              chr18                48591795         48591969        174               Pool1         0,75
  SMAD4_2\_1      ATTTAGAATGTAGGGAGGATGGGAAGA         CAGCCTTTCACAAAACTCATCCTG            chr18                48604556         48604704        148               Pool2         0,5
  SMAD4_2\_2      GACCTTCGTCGCTTATGCATACT             GGTCTGCAATCGGCATGGTA                chr18                48604658         48604820        162               Pool1         2
  SMAD4_3\_1      GTGGCTGGTCGGAAAGGATT                AACTCGTTCGTAGTGATATGGATTCAC         chr18                48575056         48575214        158               Pool2         2
  SMAD4_3\_2      CGTTTGACTTAAAATGTGATAGTGTCTGT       CGCGGGCTATCTTCCAAATTTATAAT          chr18                48575159         48575333        174               Pool1         0,5
  TP53_1\_1       GACCTAAGAGCAATCAGTGAGGAA            CATCTACAAGCAGTCACAGCAC              chr17                7578287          7578447         160               Pool1         1
  TP53_1\_2       CGCCTCACAACCTCCGTCAT                ATGTTTTGCCAACTGGCCAAG               chr17                7578406          7578533         127               Pool2         2
  TP53_2\_1       GGGATGTGATGAGAGGTGGAT               CCATCCTCACCATCATCACACTG             chr17                7577372          7577532         160               Pool1         2
  TP53_2\_2       GGCTCCTGACCTGGAGTCTT                CATCTTGGGCCTGTGTTATCTCC             chr17                7577489          7577634         145               Pool2         0,75
  TP53_3\_1       CGCTTCTTGTCCTGCTTGCTTA              TCCTATCCTGAGTAGTGGTAATCTACTG        chr17                7576996          7577170         174               Pool1         1
  TP53_3\_2       GCACCTCAAAGCTGTTCCGT                CAAGGGTGGTTGGGAGTAGATG              chr17                7577121          7577255         134               Pool2         4

As indicated, primers were designed to amplify in two separate multiplex PCR reactions. The genome position of recognition sites are provided together with their concentrations in the corresponding PCR primer pool.

###### 

All variants detected by the GS Junior panel.

  sample type   sample number   mutations (gene symbol, cDNA position, type, percentage in the sample)   other variants                                           
  ------------- --------------- ------------------------------------------------------------------------ -------------------------------- ----------------------- ---------------------------
  NAT           1               APC 3871:C/T (59%) \[germ\]                                                                                                       
  AD-LGD        9               KRAS 38:G/A (31%)                                                                                                                 
  AD-LGD        10              APC 4314:A/- (69%)                                                       KRAS 35:G/T (36%)                                        
  AD-LGD        11              KRAS 35:G/C (47%)                                                                                                                 APC SNP 4479:G/A (100%)
  AD-LGD        12              FBXW7 1513:C/T (40%)                                                     KRAS 35:G/A (49%)                                        APC SNP 4479:G/A (47%)
  AD-LGD        13              KRAS 35:G/A (31%)                                                                                                                 APC SNP 4479:G/A (47%)
  AD-LGD        14              CTNNB1 134:C/T (16%)                                                                                                              APC SNP 4479:G/A (100%)
  AD-LGD        17              APC 3927:AAAGA/\-\-\-\-- (23%)                                                                                                    
  AD-LGD        20              APC 3964:G/T (21%)                                                                                                                APC SNP 4479:G/A (100%)
  AD-LGD        21              APC 4241.:-/T (40%)                                                                                                               APC SNP 4479:G/A (61%)
  AD-LGD        22              APC 4033:G/T (38%)                                                                                                                APC SNP 4479:G/A (100%)
  AD-LGD        24                                                                                                                                                APC SNP 4479:G/A (41%)
  AD-HGD        25              SMAD4 1528:G/A (47%)                                                                                                              APC SNP 4479:G/A (79%)
  AD-HGD        26              BRAF 1799:T/A (33%)                                                                                                               APC SNP 4479:G/A (54%)
  AD-HGD        27                                                                                                                                                APC SNP 4479:G/A (99%)
  AD-HGD        28              APC 3925:G/T (26%)                                                                                                                APC SNP 4479:G/A (50%)
  AD-HGD        29              APC 3927:AAAGA/\-\-\-\-- (55%)                                           KRAS 35:G/C (29%)                                        APC SNP 4479:G/A (51%)
  AD-HGD        30              APC 3927:AAAGA/\-\-\-\-- (87%)                                           KRAS 35:G/A (35%)                SMAD4 400:G/A (82%)     
  AD-serr       31                                                                                                                                                APC SNP 4479:G/A (47%)
  AD-serr       33              BRAF 1799:T/A (29%)                                                                                                               APC SNP 4479:G/A (51%)
  AD-serr       34              BRAF 1799:T/A (4%)                                                                                                                APC SNP 4479:G/A (73%)
  AD-serr       37              APC 4348:C/T (20%)                                                       FBXW7 1745:C/T (3%)              TP53 845:G/A (6%)       
  AD-serr       38              APC 4348:C/T (4%)                                                        FBXW7 1745:C/T (9%)              TP53 845:G/A (4%)       
  AD-serr       39              CTNNB1 47:C/T (21%) \#                                                                                    TP53 845:G/A (8%)       
  AD-serr       40              FBXW7 1745:C/T (2%)                                                      TP53 845:G/A (11%)                                       
  AD-serr       41              FBXW7 1745:C/T (5%)                                                      TP53 845:G/A (4%)                                        
  CRC           42              APC 4135:G/T (73%) +                                                     FBXW7 1740:C/G (22%) \[new\] +   KRAS 35:G/A (15%) \*    
  CRC           43              APC 3927:AAAGA/\-\-\-\-- (74%) +                                         SMAD4 413:C/G (70%) \[new\] +    TP53 711:G/C (59%)      
  CRC           45              FBXW7 1393:C/T (41%)                                                     FBXW7 1745:C/T (56%)                                     
  CRC           46              TP53 814:G/A (23%)                                                                                                                APC SNP 4479:G/A (31%)
  CRC           47                                                                                                                                                APC SNP 4479:G/A (100%)
  CRC           48              TP53 733:G/A (12%)                                                                                                                APC SNP 4479:G/A (50%)
  CRC           49              APC 3916:G/T (41%) +                                                                                                              APC SNP 4479:G/A (13%) +
  CRC           50              NRAS 181:C/A (19%) \*                                                    SMAD4 1569:C/G (8%)              TP53 1538:C/T (45%)     APC SNP 4479:G/A (100%) +
  CRC           51              APC 3927:AAAGA/\-\-\-\-- (16%) +                                         FBXW7 1745:C/T (18%)             TP53 845:G/A (18%)      APC SNP 4479:G/A (100%) +
  CRC           52              TP53 845:G/A (13%)                                                                                                                APC SNP 4479:G/A (49%)
  CRC           53              KRAS 35:G/T (14%) \*                                                     TP53 814:G/A (13%)                                       APC SNP 4479:G/A (48%) +
  CRC           54                                                                                                                                                APC SNP 4479:G/A (97%)
  CRC           55              APC 3915:A/- (20%) +                                                     KRAS 35:G/A (13%) \# !           KRAS 38:G/A (6%) \* +   APC SNP 4479:G/A (47%) +
  CRC           56              KRAS 35:G/A (43%) \*                                                                                                              APC SNP 4479:G/A (74%) +
  CRC           57              KRAS 35:G/T (17%) \*                                                     SMAD4 1051:G/C (18%)             TP53 845:G/A (14%)      APC SNP 4479:G/A (32%) +
  CRC           58              BRAF 1799:T/A (35%) \*                                                   TP53 818:G/A (66%)               TP53 845:G/A (9%)       APC SNP 4479:G/A (95%) +
  cell line     59              SMAD4 1051:G/C (100%)                                                                                                             APC SNP 4479:G/A (100%)
  cell line     60              BRAF 1799:T/A (31%)                                                      TP53 818:G/A (100%)                                      APC SNP 4479:G/A (100%)

**+** : variants that have been validated by Sanger sequencing with a concordant result. \* : variants that have been validated by PyroMark pyrosequencing with a concordant result. \# : variants that have been validated by Sanger sequencing with a different result. **!** : variants that have been validated by PyroMark pyrosequencing with a different result. \[new\]: potential new mutation/not described in COSMIC or HGMD databases. \[germ\]: suspected germline mutation. NAT: normal adjacent tumor; AD-LGD: low-grade adenoma; AD-HGD: high-grade adenoma; AD-serr: serrated adenoma; CRC: colorectal cancer.

###### 

Re-sequencing primers.

  primer name         primer sequence (5\'-3\')                            Chr. Numb.   Primer 5\' Start   Primer 3\' Stop
  ------------------- ---------------------------------------------------- ------------ ------------------ -----------------
  APC_3676-4192_F     [TGTAAAACGACGGCCAGT]{.ul}CGTCCACACCTTCATCTAATGCC     5            112839246          112839269
  APC_3676-4192_R     [CAGGAAACAGCTATGACC]{.ul}GGAGCTGGCAATCGAACGAC        5            112839806          112839786
  APC_3968-4425_F     [TGTAAAACGACGGCCAGT]{.ul}CTGAAGATCCTGTGAGCGAAG       5            112839540          112839556
  APC_3968-4425_R     [CAGGAAACAGCTATGAC]{.ul}CAGAACCTGGACCCTCTGAAC        5            112840040          112840024
  APC_4296-4804_F     [TGTAAAACGACGGCCAGT]{.ul}AGCCCTGGACAAACCATGCC        5            112839869          112839889
  APC_4296-4804_R     [CAGGAAACAGCTATGAC]{.ul}CGGTTTCCTTGCCACAGGTGGAG      5            112840421          112840398
  CTNNB1_14-241_F     [TGTAAAACGACGGCCAGT]{.ul}TTGGCTGTCTTTCAGATTTG        3            41224400           41224419
  CTNNB1_14-241_R     [CAGGAAACAGCTATGAC]{.ul}CTGACTTTCAGTAAGGCAATG        3            41224771           41224790
  SMAD4_250-424_F     [TGTAAAACGACGGCCAGT]{.ul}CTGAGTTGGTAGGATTGTGAG       18           51048594           51048615
  SMAD4_250-424_R     [CAGGAAACAGCTATGAC]{.ul}CTATAATGCTTTCCATCTTATTTCTC   18           51049096           51049121
  FBXW7_1645-1855_F   [TGTAAAACGACGGCCAGT]{.ul}ACCTGTTTCCCATCCTCTTCC       4            152324496          152324476
  FBXW7_1645-1855_R   [CAGGAAACAGCTATGAC]{.ul}CTGTGATGCTAAGGCTCCATATTTC    4            152324128          152324105
  KRAS_F              GGCCTGCTGAAAATGACTGA                                 12           25245396           25245376
  KRAS_R\_Biotin      biotin-AGCTGTATCGTCAAGGCACTCT                        12           25245316           25245338
  KRAS_seq            AAACTTGTGGTAGTTGGA                                   12           25245372           25245354
  NRAS_F              GATTCTTACAGAAAACAAGTGGTTATAGAT                       1            114713978          114713948
  NRAS_R\_Biotin      biotin-GCAAATACACAGAGGAAGCCTTCG                      1            114713841          114713865
  NRAS_seq            CTGTTTGTTGGACATACTG                                  1            114713940          114713921
  BRAF_F              TGAAGACCTCACAGTAAAAATAGG                             7            140753380          140753356
  BRAF_R\_Biotin      biotin-TCCAGACAACTGTTCAAACTGAT                       7            140753289          140753312
  BRAF_seq            TGATTTTGGTCTAGCTACA                                  7            140753356          140753337

List of primers used to validate GS Junior sequencing results. The sequence of universal 5\' M13 tags are underlined. The position of primers refers to the GRCh38/hg83 genome. Chr. Numb.: chromosome number; F: forward; R: reverse; Biotin: 5\' biotin tag; seq: sequencing primer.
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